



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE				Attorney Docket No.	50059/007002		
				Serial No.	09/830,400		
				Applicant	Lee Nadler et al.		
				Filing Date	April 25, 2001		
				Group	Not Yet Assigned		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				IDS Filed	May 15, 2001		
(37 C.F.R. §1.98(b))				Customer No.	21559		
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
AJ	5,679,647	10/21/97	Carson et al.				
AJ	5,747,317	05/05/98	Cao				
AJ	5,770,422	06/23/98	Collins				
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
AJ	Bohm et al., "Identification of HLA-A2-Restricted Epitopes of the Tumor-Associated Antigen MUC2 Recognized by Human Cytotoxic T Cells," <i>International J. of Cancer</i> 75:688-693 (1998).						
AJ	Brunette et al., "Immunotherapy (Cancer): Tumor Antigen Specific Immunotherapy of Cancer: Peptide and Gene Based Modification of Dendritic Cells as Antigen Presenting Cells," <i>Cancer Biotechnology Weekly</i> p16 (1996).						
AJ	Celis et al., "Identification of Potential CTL Epitopes of Tumor-Associated Antigen MAGE-1 for Five Common HLA-A Alleles," <i>Molecular Immunology</i> 31:1423-1430 (1994).						
AJ	Herlyn et al., "Epitope- and Antigen-Specific Cancer Vaccines," <i>International Review of Immunology</i> 7:245-257 (1991).						
EXAMINER /Amy Juedes/			DATE CONSIDERED		/Amy Juedes/		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							



21559

PATENT TRADEMARK OFFICE



AUG 02 2001

PATENT & TRADEMARK OFFICE

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Attorney Docket No.	50059/007002
		Serial No.	09/830,400
		Applicant	Lee M. Nadler et al.
		Filing Date	April 25, 2001
		Group	Not Yet Assigned
(37 C.F.R. §1.98(b))		IDS Filed	July 30, 2001
		Customer No.	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
AJ	WO 98/14593	09.04.98	WIPO			No
AJ	WO 98/37181	27.08.98	WIPO			No

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

Schultze et al., "Autologous Adoptive T Cell Transfer For A Patient With Plasma Cell Leukemia: Results Of A Pilot Phase I Trial," <i>Therapy of Chronic Lymphocytic Leukemia And Multiple Myeloma</i> p. 109a Poster Board#/Session 446-I.
Vonderheide et al., "The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-associated Antigen Recognized By Cytotoxic T Lymphocytes," <i>Immunity</i> 10:673-679 (1999).

EXAMINER	/Amy Juedes/	DATE CONSIDERED	09/21/2006
----------	--------------	-----------------	------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

Please type a plus sign (+) in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

O I P E
FEB 11 2003
JC22
PATENT & TRADEMARK OFFICE

Modified Form 1449/PTO		Application Number	09/830,400
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 25, 2001
		First Named Inventor	Nadler, et al.
		Group Art Unit	1642
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	110-19 2003 20363-015 NATL
(use as many sheets as necessary)		RECEIVED	

U.S. PATENT DOCUMENTS					TECH CENTER 1600/2900		
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date mm/dd/yyyy	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate mm/dd/yyyy

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No
	B3	EP 1093381	Norsk Hydro ASA	04/25/2001	
AJ	B4	WO 99/50392	Geron Corp.	10/07/1999	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
AJ	C7	Brossart, et al. (1998). "Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes." <i>Cancer Research</i> . 58(4):732-736.			
	C8	Jensen, et al. (1998). "A europium fluoroimmunoassay for measuring peptide binding to MHC class I molecules." <i>Journal of Immunological Methods</i> . 215(1-2):71-80.			
	C9	Kawashima, et al. (1998). "The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors." <i>Human Immunology</i> . 59(1):1-14.			
	C10	Kim, et al. (1994). "Specific association of human telomerase activity with immortal cells and cancer." <i>Science</i> . 266:2011-2015.			
	C11	Schultze, et al. (1997). "CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy." <i>Journal of Clinical Investigation</i> . 100(11):2757-2765.			
	C12	Schultze, et al. (1997). "Vaccination as immunotherapy for B cell lymphoma." <i>Hematological Oncology</i> . 15(3):129-139.			
AJ	C13	Vonderheide, et al. (1999). "Generation of telomerase-specific HLA-A3-restricted cytotoxic T lymphocytes from patient blood: implications for widely applicable anti-cancer immunotherapy." <i>Forty-first annual meeting of the American Society of Hematology</i> ; New Orleans. 94(10):677a.			
	C14	Supplementary Partial European Search Report for Application No. EP 00-05-0777. Mailed on 11/11/2002.			

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Amy Juedes/	Date Considered	09/21/2006
--------------------	--------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.